The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Cymevene 500 mg powder for concentrate for solution for infusion

CHEPLAPHARM Arzneimittel GmbHPA2239/003/001

Main Information

Trade NameCymevene 500 mg powder for concentrate for solution for infusion
Active SubstancesGanciclovir
Dosage FormPowder for concentrate for solution for infusion
Licence HolderCHEPLAPHARM Arzneimittel GmbH
Licence NumberPA2239/003/001

Group Information

ATC CodeJ05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB06 ganciclovir


License statusAuthorised
Licence Issued17/08/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back